Venus Remedies Ltd has secured a marketing authorisation from Saudi Arabia, the largest market in the Gulf Cooperation Council (GCC) region for Docetaxel, a widely used chemotherapy drug.
The development comes three months after the company received good manufacturing practices (GNP) certification from the Saudi Food and Drug Authority (SFDA) for all its production facilities at its unit in Baddi, Himachal Pradesh.
The demand for Docetaxel has been steadily increasing the world over with the rising incidence of breast, prostate, stomach and non-small cell lung cancers, for which this chemotherapy drug is used as a first line of treatment. Docetaxel-based treatment has particularly improved the survival rate among men in castration-sensitive prostate cancers. The $102-billion global Docetaxel market is projected to grow to $184 billion by year 2030 at a CAGR of 10.22%.
The marketing approval for Docetaxel from Saudi Arabia, a $7.8-billion pharmaceutical market (as in 2021 ) which is expected to grow to $13.1 billion by 2031 at a CAGR of 5.4 per cent, signifies a major step in the global expansion strategy of Venus Remedies in the oncology space. Hailing the achievement, Saransh Chaudhary, President Global Critical Care, Venus Remedies, said, “This approval will enable us to solidify our existing foothold in the GCC and Middle East and North Africa (MENA) regions by sti.eamlining the registration process for our oncology drugs there, ultimately benefiting a large population in need of advanced cancer treatments.”
Since Saudi Arabia also happens to be the leading country in the Gulf in terms of quality benchmarks,
this approval is expected to pave the way for marketing authorisations from other countries in the GCC and MENA regions which consider SFDA as a reference authority.
Venus Remedies has, off late, been rapidly consolidating its position in the oncology space. Its German subsidiary Venus Pharma GmbH had secured a marketing authorisation from the UK for key chemotherapy drug Cisplatin only last month, thus expediting the process of registering its oncology products in many other countries which consider the UK as a reference point for fast-tracking registration. The company followed this up with marketing authorisation for two more widely used cancer drugs from Philippines, the second largest market in the ASEAN region, and lraq, a sizeable market in the MENA zone.
Be First to Comment